Namwiwat Medical vs Danaher: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Namwiwat Medical (NAM.BK)

Q3 202621 Jul – 29 Sep 2026

▲4

NAM pushes overseas expansion and new products as Q2 profit jumps

Italy subsidiary opens Europe, Indonesia base planned NAM set up a fully owned subsidiary in Italy to sell into Europe, and is weighing direct investment in Indonesia after starting assembly there. Foreign sales are only about 5% of revenue now, so success would add a new growth source beyond Thailand.
This is the main new force behind NAM's growth story this period.
PTT purchase deal for enzymatic cleaning solution PTT signed a purchase agreement for NAM's multi-enzyme medical instrument cleaning solution, which has passed international testing. A big local partner buying the product secures orders, cuts Thailand's reliance on imports, and supports NAM's sales and reputation.
A concrete new order from a major partner directly supports revenue.
Q2 profit nearly triples, H2 seen stronger Second-quarter profit rose to 29.5 million baht from 12.5 million a year earlier, and management expects faster growth in the second half on government spending and overseas sales, with margins helped by lower production costs. Note first-half profit still fell year-on-year.
Earnings are the clearest evidence of whether the growth plans are working.
Five-pillar strategy targets 380m baht profit by 2028 NAM laid out five growth engines: wider product range, brand building, overseas expansion via Malaysia and Italy subsidiaries plus an Indonesia assembly base, partnerships, and cost control. It targets 2.4 billion baht 2026 revenue and 380 million baht net profit by 2028, backed by 150 million baht capex.
The strategy and long-term targets frame how the new expansion is meant to pay off.

August 202621 Jul – 29 Sep 2026

▲4

NAM pushes overseas expansion and new products as Q2 profit jumps

Italy subsidiary opens Europe, Indonesia base planned NAM set up a fully owned subsidiary in Italy to sell into Europe, and is weighing direct investment in Indonesia after starting assembly there. Foreign sales are only about 5% of revenue now, so success would add a new growth source beyond Thailand.
This is the main new force behind NAM's growth story this period.
PTT purchase deal for enzymatic cleaning solution PTT signed a purchase agreement for NAM's multi-enzyme medical instrument cleaning solution, which has passed international testing. A big local partner buying the product secures orders, cuts Thailand's reliance on imports, and supports NAM's sales and reputation.
A concrete new order from a major partner directly supports revenue.
Q2 profit nearly triples, H2 seen stronger Second-quarter profit rose to 29.5 million baht from 12.5 million a year earlier, and management expects faster growth in the second half on government spending and overseas sales, with margins helped by lower production costs. Note first-half profit still fell year-on-year.
Earnings are the clearest evidence of whether the growth plans are working.
Five-pillar strategy targets 380m baht profit by 2028 NAM laid out five growth engines: wider product range, brand building, overseas expansion via Malaysia and Italy subsidiaries plus an Indonesia assembly base, partnerships, and cost control. It targets 2.4 billion baht 2026 revenue and 380 million baht net profit by 2028, backed by 150 million baht capex.
The strategy and long-term targets frame how the new expansion is meant to pay off.

Latest21 Jul – 29 Sep 2026

▲4

NAM pushes overseas expansion and new products as Q2 profit jumps

Italy subsidiary opens Europe, Indonesia base planned NAM set up a fully owned subsidiary in Italy to sell into Europe, and is weighing direct investment in Indonesia after starting assembly there. Foreign sales are only about 5% of revenue now, so success would add a new growth source beyond Thailand.
This is the main new force behind NAM's growth story this period.
PTT purchase deal for enzymatic cleaning solution PTT signed a purchase agreement for NAM's multi-enzyme medical instrument cleaning solution, which has passed international testing. A big local partner buying the product secures orders, cuts Thailand's reliance on imports, and supports NAM's sales and reputation.
A concrete new order from a major partner directly supports revenue.
Q2 profit nearly triples, H2 seen stronger Second-quarter profit rose to 29.5 million baht from 12.5 million a year earlier, and management expects faster growth in the second half on government spending and overseas sales, with margins helped by lower production costs. Note first-half profit still fell year-on-year.
Earnings are the clearest evidence of whether the growth plans are working.
Five-pillar strategy targets 380m baht profit by 2028 NAM laid out five growth engines: wider product range, brand building, overseas expansion via Malaysia and Italy subsidiaries plus an Indonesia assembly base, partnerships, and cost control. It targets 2.4 billion baht 2026 revenue and 380 million baht net profit by 2028, backed by 150 million baht capex.
The strategy and long-term targets frame how the new expansion is meant to pay off.

Danaher Corporation (DHR)

Q3 202624 Jun – 8 Oct 2026

▲2▼2

Danaher's mixed Q3: biotech growth offset by guidance cuts and Masimo deal concerns

Biotech growth and product clearances Danaher's biotech segment grew 7% with strong bioprocessing orders, and it won FDA clearance for Masimo's AI opioid-detection feature and a CE Mark for Beckman Coulter's Alzheimer's blood test, signaling innovation momentum.
These positive developments show underlying demand and product progress that supported the stock.
Strategic acquisitions and AI lab launch Leica Biosystems closed its StatLab acquisition, and Danaher launched its first AI-powered autonomous antibody lab at Abcam, potentially making custom antibodies up to 8x faster, which could drive future efficiency and growth.
These moves expand Danaher's capabilities and may enhance long-term competitiveness.
Guidance cuts and revenue shift Danaher twice cut core growth guidance due to weak respiratory testing and over $100 million in bioprocessing revenue shifting to 2027, while biotech consumables missed on shipment timing, raising doubts about the recovery pace.
These cuts directly lowered expectations and pressured the stock.
Masimo acquisition concerns The $9.9 billion Masimo acquisition weighed on shares amid debt, integration, and Apple patent concerns, adding uncertainty and financial risk.
The large deal introduced balance sheet and legal risks that investors worried about.

September 202610 Aug – 8 Oct 2026

▲3▼1

Danaher trims growth outlook, but AI lab and deal build new story

Danaher cuts core growth guidance as recovery lags peers Danaher lowered the top of its full-year core revenue growth outlook to 3%-4% from 3%-6%, blaming weaker respiratory testing and a $100 million order pushed into next year. Thermo Fisher and Medtronic raised guidance, so investors see Danaher's recovery as slower and less certain, which weighs on the stock.
This is the main negative force this period and explains why the stock lagged peers.
Leica Biosystems closes StatLab acquisition Danaher's Leica Biosystems completed its purchase of StatLab Medical Products, adding pre-analytical consumables and equipment to its pathology business. It expands Danaher's diagnostics offerings and cross-selling opportunities, a modest positive that supports long-term revenue growth even if it doesn't change near-term numbers much.
A concrete completed deal that adds to Danaher's diagnostics portfolio and future revenue.
First AI-powered autonomous lab for antibody research Danaher announced its first AI-powered autonomous lab at Abcam, combining AI, robotics and its operating companies' tools to make custom antibodies up to 8x faster. It signals a higher-value, automation-led growth story, and the stock rose about 2% premarket on the news, though real revenue is not expected until early 2027.
This is the clearest new positive catalyst and shows Danaher's AI/automation strategy.
Barclays raises Danaher price target to $255 Barclays lifted its Danaher price target to $255 from $230 while keeping an Overweight rating, citing confidence in the company's outlook. Analyst upgrades can draw in buyers and support the share price, though they reflect opinion rather than a change in Danaher's actual business results.
A fresh analyst move that can influence near-term investor demand for the stock.

Latest10 Aug – 8 Oct 2026

▲3▼1

Danaher trims growth outlook, but AI lab and deal build new story

Danaher cuts core growth guidance as recovery lags peers Danaher lowered the top of its full-year core revenue growth outlook to 3%-4% from 3%-6%, blaming weaker respiratory testing and a $100 million order pushed into next year. Thermo Fisher and Medtronic raised guidance, so investors see Danaher's recovery as slower and less certain, which weighs on the stock.
This is the main negative force this period and explains why the stock lagged peers.
Leica Biosystems closes StatLab acquisition Danaher's Leica Biosystems completed its purchase of StatLab Medical Products, adding pre-analytical consumables and equipment to its pathology business. It expands Danaher's diagnostics offerings and cross-selling opportunities, a modest positive that supports long-term revenue growth even if it doesn't change near-term numbers much.
A concrete completed deal that adds to Danaher's diagnostics portfolio and future revenue.
First AI-powered autonomous lab for antibody research Danaher announced its first AI-powered autonomous lab at Abcam, combining AI, robotics and its operating companies' tools to make custom antibodies up to 8x faster. It signals a higher-value, automation-led growth story, and the stock rose about 2% premarket on the news, though real revenue is not expected until early 2027.
This is the clearest new positive catalyst and shows Danaher's AI/automation strategy.
Barclays raises Danaher price target to $255 Barclays lifted its Danaher price target to $255 from $230 while keeping an Overweight rating, citing confidence in the company's outlook. Analyst upgrades can draw in buyers and support the share price, though they reflect opinion rather than a change in Danaher's actual business results.
A fresh analyst move that can influence near-term investor demand for the stock.

July 202624 Jun – 4 Aug 2026

▼3▲1

Danaher's Masimo Deal and Guidance Cut Pressure Shares

Masimo Acquisition Drag Danaher's $9.9 billion purchase of Masimo sent shares down 22% due to debt, integration challenges, and Apple patent disputes. This major deal overshadowed positive product news.
The acquisition is the biggest new event and main reason for the stock's decline.
Guidance Cut on Weak Respiratory Testing Danaher lowered its full-year core revenue growth forecast to 4% from 6%, blaming weaker respiratory testing and over $100 million in bioprocessing revenue shifting to 2027.
This guidance cut directly impacts investor expectations and the stock's valuation.
Biotech Consumables Shipment Timing Miss Biotech consumables missed expectations due to shipment timing, raising fears of broader weakness despite strong underlying demand. This added to concerns about the bioprocessing business.
The miss highlights execution risks and weighs on sentiment.
Strong Biotech Growth and Product Approvals Danaher posted 7% core biotech growth, strong bioprocessing orders, FDA clearance for Masimo's AI opioid-detection feature, and a CE Mark for Beckman Coulter's Alzheimer's blood test. Q2 EPS beat and guidance was raised.
These positives show underlying business strength and innovation, providing a counterweight to the negatives.

25 Jul – 4 Aug 2026

▲3▼1

Danaher cuts growth outlook, but core biotech and diagnostics still support

Full-year core revenue growth outlook cut to 4% from 6% Danaher lowered the top end of its 2026 core revenue growth forecast to 4% from 6%, citing weaker respiratory testing and over $100 million in bioprocessing revenue shifting to next year. This signals slower demand ahead, pushing the stock down as investors worry about future growth.
This is the main new negative event that directly answers why DHR is moving right now.
Q2 earnings beat and raised EPS guidance Danaher reported adjusted EPS of $1.94, beating estimates, and raised full-year EPS guidance to $8.45–$8.60. This shows the core business remains profitable and resilient, which could support the stock once the sell-off settles.
This is a new positive counterweight that helps explain the mixed picture and potential support for the stock.
Biotech orders grow mid-teens, but revenue timing shifts Danaher's bioprocessing orders grew mid-teens, indicating strong underlying demand, but weaker-than-expected biotechnology revenue and a shift of over $100 million into next year weighed on results. This creates a mixed picture: strong future demand but near-term revenue miss.
This explains the nuance behind the revenue miss and why the stock reaction may be overdone.
Analysts see stock as undervalued after sell-off A Simply Wall St analysis suggests Danaher is 16% undervalued based on earnings and 2026 revenue guidance, with a fair value estimate of $228.61. BofA maintained a Buy rating but cut its price target to $230 from $270. This could attract value investors and support the stock.
This provides a potential positive catalyst and shows analyst views on valuation after the decline.

17 Jul – 24 Jul 2026

▲2▼2

Danaher's Q2 Beat Marred by Weak Guidance and Biotech Shipment Shift

Weak Q3 revenue guidance triggers sell-off Danaher guided Q3 core revenue growth to just 2-3%, far below expectations, despite beating Q2 estimates. This signals slower demand ahead, pushing the stock down sharply as investors worry about future growth.
This is the main new event that caused the stock to drop over 10% this period.
Biotech consumables sales miss due to shipment timing High-margin biotech consumables missed expectations because a few large chromatography resin shipments moved out of the year. This reduces near-term revenue and profit, and the market fears it could signal broader weakness.
This explains the specific reason behind the guidance cut and the stock's decline.
Q2 earnings beat and raised full-year EPS guidance Danaher reported adjusted EPS of $1.94, beating estimates, and raised full-year EPS guidance to $8.45-$8.60. This shows the core business remains profitable and resilient, which could support the stock once the sell-off settles.
This is a key positive from the quarter that contrasts with the negative reaction.
Analysts see sell-off as overreaction and buying opportunity The 12% weekly drop is viewed by some analysts as an overreaction to a timing issue, not a fundamental problem. If shipments shift to later quarters, revenue will still be recognized, making the decline a potential buying opportunity for long-term investors.
This provides a counterweight to the negative news and suggests the stock may rebound.

24 Jun – 9 Jul 2026

▲3▼1

Danaher's Masimo Bet Faces Doubts as Core Biotech Shows Strength

Masimo acquisition drags on stock Danaher's $9.9 billion purchase of Masimo has pushed shares down 22% this year. Investors worry about added debt, integration challenges, and a patent fight with Apple. This weighs on the stock because it increases risk and uncertainty.
Explains the main reason DHR is down this year and the key overhang on the stock.
Masimo unit gets FDA clearance for AI opioid detection Masimo received FDA clearance for an AI feature that detects opioid-induced breathing problems. This is a first-of-its-kind product that could boost sales and shows the acquisition is already producing innovative products, lifting investor sentiment.
Shows a concrete positive from the Masimo deal that could drive future revenue and improve sentiment.
Biotech segment core revenues grow 7% Danaher's Biotechnology segment saw core revenues rise 7% in Q1 2026, with bioprocessing equipment orders up over 30%. This indicates strong demand for the company's core products, which supports revenue growth and profitability, pushing the stock up.
Highlights the strong performance of Danaher's core business, a key driver of earnings and stock price.
Beckman Coulter wins CE Mark for Alzheimer's blood test Danaher's Beckman Coulter received CE Mark for its p-Tau217 blood assay, allowing sales in Europe. This regulatory win opens a new market for a potentially high-demand Alzheimer's test, adding a future revenue stream and boosting the stock.
Represents a new product approval that expands Danaher's diagnostics offerings and could drive growth.